SKYE · Company research
Skye Bioscience, Inc. Common Stock (SKYE): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
16records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Two holders report shared voting power over the same 263,560 Skye Bioscience (SKYE) shares. - Stock Titan | Two holders report shared voting power over the same 263,560 Skye Bioscience (SKYE) shares. Stock Titan | View source ↗ | Stock Titan | Oct 14, 2026 | neutral | 0 | 0.6 |
| Skye Bioscience director Andrew Schwab sells $239,555 in common stock - Investing.com | Skye Bioscience director Andrew Schwab sells $239,555 in common stock Investing.com | View source ↗ | Investing.com | Sep 25, 2026 | neutral | 0 | 0.6 |
| Two 5AM funds sold Skye Bioscience (SKYE) shares; one day's weighted average price was $1.61. - Stock Titan | Two 5AM funds sold Skye Bioscience (SKYE) shares; one day's weighted average price was $1.61. Stock Titan | View source ↗ | Stock Titan | Sep 24, 2026 | neutral | 0 | 0.6 |
| 5AM funds sell Skye Bioscience (SKYE) shares after reverse split - Stock Titan | 5AM funds sell Skye Bioscience (SKYE) shares after reverse split Stock Titan | View source ↗ | Stock Titan | Sep 18, 2026 | neutral | 0 | 0.6 |
| Skye Bioscience CFO Resigns, CEO Assumes Financial Role - The Globe and Mail | Skye Bioscience CFO Resigns, CEO Assumes Financial Role The Globe and Mail | View source ↗ | The Globe and Mail | Sep 12, 2026 | neutral | 0 | 0.6 |
| Skye Bioscience Secures Up to $22 Million ELOC and Issues $5 Million Warrant to Redmile - TradingView | Skye Bioscience Secures Up to $22 Million ELOC and Issues $5 Million Warrant to Redmile TradingView | View source ↗ | TradingView | Aug 24, 2026 | neutral | 0 | 0.6 |
| Insider Sale: Director at $SKYE Sells 46 Shares | SKYE Stock News - Quiver Quantitative | Insider Sale: Director at $SKYE Sells 46 Shares | SKYE Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 20, 2026 | neutral | 0 | 0.6 |
| 5am Partners VII, LLC sells $140,313 of Skye Bioscience stock - Investing.com | 5am Partners VII, LLC sells $140,313 of Skye Bioscience stock Investing.com | View source ↗ | Investing.com | Aug 20, 2026 | neutral | 0 | 0.6 |
| Skye Bioscience receives Nasdaq notice for non-compliance with equity listing rule - Investing.com | Skye Bioscience receives Nasdaq notice for non-compliance with equity listing rule Investing.com | View source ↗ | Investing.com | Aug 19, 2026 | neutral | 0 | 0.6 |
| Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings - GlobeNewswire | Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings GlobeNewswire | View source ↗ | GlobeNewswire | Aug 14, 2026 | neutral | 0 | 0.6 |
| Skye Bioscience and Redx Pharma to merge - The Pharma Letter | Skye Bioscience and Redx Pharma to merge The Pharma Letter | View source ↗ | The Pharma Letter | Aug 14, 2026 | neutral | 0 | 0.6 |
| Skye Bioscience to Acquire Redx; Secures $67.9M Financing and $22M Equity Line - TradingView | Skye Bioscience to Acquire Redx; Secures $67.9M Financing and $22M Equity Line TradingView | View source ↗ | TradingView | Aug 14, 2026 | neutral | 0 | 0.6 |
| Skye Bioscience, Inc. 2026: Revenue $178.2K, EPS ($0.27) — 10-Q Summary - TradingView | Skye Bioscience, Inc. 2026: Revenue $178.2K, EPS ($0.27) — 10-Q Summary TradingView | View source ↗ | TradingView | Aug 14, 2026 | neutral | 0 | 0.6 |
| Skye Bioscience (SKYE) Edges Higher as Stock Holds Above Key Support at $0.63 - Daily Profile - www.dars.gov.et | Skye Bioscience (SKYE) Edges Higher as Stock Holds Above Key Support at $0.63 - Daily Profile www.dars.gov.et | View source ↗ | www.dars.gov.et | Jul 20, 2026 | neutral | 0 | 0.6 |
| Here's Why Skye Bioscience (NASDAQ:SKYE) Must Use Its Cash Wisely - Simply Wall Street | Here's Why Skye Bioscience (NASDAQ:SKYE) Must Use Its Cash Wisely Simply Wall Street | View source ↗ | Simply Wall Street | Feb 4, 2026 | neutral | 0 | 0.6 |
| Skye links CB1-Wegovy combo to 22.3% weight loss after a year in extension of failed ph. 2 study - Fierce Biotech | Skye links CB1-Wegovy combo to 22.3% weight loss after a year in extension of failed ph. 2 study Fierce Biotech | View source ↗ | Fierce Biotech | Feb 2, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.